Compare NC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | IPSC |
|---|---|---|
| Founded | 1913 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.8M | 441.9M |
| IPO Year | 2006 | 2021 |
| Metric | NC | IPSC |
|---|---|---|
| Price | $47.33 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 11.9K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 1.17 | N/A |
| Revenue | $104,778,000.00 | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $35.43 | $0.44 |
| 52 Week High | $59.42 | $2.97 |
| Indicator | NC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 46.39 |
| Support Level | $47.53 | $2.14 |
| Resistance Level | $51.09 | $2.56 |
| Average True Range (ATR) | 1.52 | 0.19 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 31.80 | 18.67 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.